Comparative efficacy and safety of anti-infective drugs for patients with mild to severe COVID-19: A systematic review and network meta-analysis of randomized controlled trials
Ethiop. Med. j
;
61(2): 171-188, 2023. tables, figures
Article
Dans Anglais
| AIM
| ID: biblio-1426999
ABSTRACT
Different anti-infecthe drugs have been proposedfor the treatment ofpatients with COVID-19. We carried out a network meta-analysis to assess their relath'e efficacy and safety. Methods:
We searched relevant databases for all randomized controlled trials that reported the efficacy and or safety ofany anti-infective drugs published up to April 30, 2022 for different outcomes. We did both painvise and network meta-analysis with 95% confidence intervals using afixed-effect model. We assessed studies for quality of evidence using an extension of the standard Grading ofRecommendations, Assessment, Development and Evaluation approach considering PConclusion:
This Network Meta-analysis suggests that Baricitinib plus Remdesivir is more effective than the other anti-infective drugs in treating patients with COVID-19 in terms of clinical recovery at 14 days, mortality and adverse events outcomes.
Texte intégral
- https://indexmedicus.afro.who.int/iah/fulltext/Comparative efficacy and safety of anti infective drugs for patients with mild to severe COVID 19 A systematic review and network meta analysis of randomized controlled trials.pdf
- https://emjema.org/index.php/EMJ/article/view/2211/897
- https://fi-admin.bvsalud.org/document/view/cm8uy
Texte intégral:
Disponible
Indice:
AIM (Afrique)
Sujet Principal:
Essai contrôlé randomisé
/
COVID-19
/
Traitements médicamenteux de la COVID-19
Type d'étude:
Essai clinique contrôlé
/
Revues systématiques évaluées
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Ethiop. Med. j
Année:
2023
Type:
Article
Institution/Pays d'affiliation:
Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University/ET
/
Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences,/ET
/
Department of Statistics, Addis Ababa University, Addis Ababa/ET
/
ICenter for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), College of Health Sciences, Addis Ababa University, Addis Ababa/ET
/
School of Psychology, Addis Ababa University, Addis Ababa/ET
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS